Lantern Pharma
Dr. Silberstein has served as a director since June 2018. Dr. Silberstein has served as a chief operating officer of BioMimetix Pharmaceutical, Inc. since 2013. Dr. Silberstein has served as a director of BMI since 2016. Dr. Silberstein received his Ph.D. in Immunology at Columbia University and Postdoctoral training at Harvard Medical School/Brigham & Women’s Hospital.
Dr. Silberstein continued for seven years at Harvard, leading a research team studying the biochemistry of inflammation. This was followed by 20 years at AstraZeneca Pharmaceuticals where Dr. Silberstein had leadership roles in genomics, translational science, company-wide portfolio management, and science support for two products through launch to aggregate sales of greater than $30 billion.
Since 2013, Dr. Silberstein has worked independently with a number of early-stage biotech companies and as a consultant to investment firms. Current work includes his role as Principal Investigator of an NCI-funded clinical trial in patients with multiple brain metastases.
This person is not in the org chart
This person is not in any teams
This person is not in any offices
Lantern Pharma
24 followers
Lantern Pharma, Inc. is a clinical-stage pharmaceutical company developing new classes of precision cancer drugs with novel mechanisms of action, and also rescuing or revitalizing abandoned or failed cancer drugs using machine learning techniques, genomic data, and precision oncology trials. Lantern is focused on accelerating personalized cancer therapy development through the use of AI and genomic-based patient stratification.